Výsledky vyhledávání

Akademický článek

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

Autor: Koji Matsumoto, Masato Takahashi, Kazuhiko Sato, Akihiko Osaki, Toshimi Takano, Yoichi Naito, Kazuo Matsuura, Kenjiro Aogi, Kimiko Fujiwara, Kenji Tamura, Motoi Baba, Shinya Tokunaga, Gen Hirano, Shigeru Imoto, Chieko Miyazaki, Kazuhiro Yanagihara, Chiyo K. Imamura, Yasutaka Chiba, Toshiaki Saeki

Publikováno v: Cancer Medicine, Vol 9, Iss 10, Pp 3319-3327 (2020)

Abstract Purpose To investigate whether palonosetron is better than granisetron in preventing chemotherapy‐induced nausea and vomiting (CINV) in a three‐drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer wh

Externí odkaz: https://doaj.org/article/353ada2164d44028a326c1d96309f033

Zobrazit plný text záznamu

Plný text ve formátu HTML

Novel doxorubicin / folate-targeted trans-ferulic acid-loaded PLGA nanoparticles combination: In-vivo superiority over standard chemotherapeutic regimen for breast cancer treatment

Autor: Amal M El Gayar, Ibrahim M. El-Sherbiny, Sahar A. Helmy, Yousra M. El-Far, Saif El-Mofty

Publikováno v: Biomedicine & Pharmacotherapy, Vol 145, Iss, Pp 112376-(2022)

Aim Doxorubicin/Cyclophosphamide (AC) is one of the standard adjuvant anthracycline-containing regimens that is still in use for breast cancer treatment. Cancer cell resistance and AC-induced side effects make treatment suboptimal and worsen patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5051d570b440a4eb4e2033d4086ed95a
http://www.sciencedirect.com/science/article/pii/S0753332221011604

Zobrazit plný text záznamu

Abstract SS1-06: Racial disparities in pathological complete response among breast cancer patients receiving neoadjuvant chemotherapy

Autor: Meghan Steiner, Rita Nanda, Olufunmilayo I. Olopade, Gini F. Fleming, Nora Jaskowiak, Abiola Ibraheem, Dezheng Huo, Fangyuan Zhao

Publikováno v: Cancer Research. 81:SS1-06

Background: With the increasing use of neoadjuvant chemotherapy in breast cancer patients, it is important to better understand how host factors interact with tumor characteristics to determine response to neoadjuvant chemotherapy. Pathological compl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::175cd754ab0682693e9db3365732d2a6
https://doi.org/10.1158/1538-7445.sabcs20-ss1-06

Zobrazit plný text záznamu

Experimental, Clinical, and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer

Autor: A. M. Zhumakayeva, I. M. Omarova, Kayrolla D. Rakhimov, S. M. Adekenov, L. I. Arystan

Publikováno v: Open Access Macedonian Journal of Medical Sciences
Open Access Macedonian Journal of Medical Sciences; Vol. 8 No. B (2020): B-Clinical Sciences; 1077-1082
Open Access Macedonian Journal of Medical Sciences, Vol 7, Iss 19 (2019)
Open Access Macedonian Journal of Medical Sciences; Vol. 7 No. 19 (2019): Oct 15 (OAMJMS); 3153-3157

BACKGROUND: Activated forms of RAS increase both in breast cancer and in cell lines in the presence of estimated glomerular filtration rate (EGFR) or HER2 expression. HRAS oncoproteins play an important role in enhancing the proliferation and resista

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195a384386b602a5caeb7524b25ccbcf
https://doi.org/10.3889/oamjms.2020.4969

Zobrazit plný text záznamu

Neoadjuvant Therapy with Drug Arglabin for Breast Cancer with Expression of H-Ras Oncoproteins

Autor: Vladimir Perminov, Ainur Zhumakayeva, Kayrolla D. Rakhimov, Bakhytzhan Bekmanov, Sergazy Adekenov

Publikováno v: Asian Pacific Journal of Cancer Prevention : APJCP

Backgrounds In breast cancer, blocking of Ras signaling and inhibition of H-Ras is quite promising. H-Ras may become a target for farnesyl transferase inhibitors, and in combination with other immunohistochemical factors it will contribute to the pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce2e4bd820d9a2f0901493bf06a122aa
http://europepmc.org/articles/PMC8033125

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers

Autor: Maria Isabel Fiel, Celina Ang, Umut Ozbek, Jung-Yi Lin, William Miller, Nebras Zeizafoun, Alexandros D. Polydorides, Huili Zhu, Sanders Chang, Noam Harpaz, Sheena Bhalla, Ippolito Modica, Wen Fan, Xiuxu Chen, Eric J. Wilck, Stephen C. Ward

Publikováno v: Cancer Reports
Cancer Reports, Vol 4, Iss 6, Pp n/a-n/a (2021)

Background Neoadjuvant chemotherapy (NAC) is frequently used in gastrointestinal cancers (GIC), and pathological, radiological, and tumor marker responses are assessed during and after NAC. Aim To evaluate the relationship between pathologic, radiolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0914e6bce32b0562fa84fa00f7ba055a
http://europepmc.org/articles/PMC8714550

Zobrazit plný text záznamu

Management of anticoagulation associated reproductive tract bleeding in adolescent and young adult females - Results of a multinational survey

Autor: Ayesha Zia, Madhvi Rajpurkar, Angela C. Weyand, Lakshmi Srivaths, Peter A. Kouides, Sarah H. O'Brien, Ronald Thomas

Publikováno v: Thrombosis research. 203

Introduction Reproductive tract bleeding (RTB) is an important outcome in menstruating females on anticoagulant therapy (AC). The diagnosis and management of AC-RTB in adolescent and young adult (AYA) females is unknown. Aims The aim of this study wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::432f986e1d5b1ce0803feaadf728e00d
https://pubmed.ncbi.nlm.nih.gov/33957308

Zobrazit plný text záznamu

Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer

Autor: I. A. Koroleva, M. V. Kopp, A. M. Koroleva

Publikováno v: Медицинский совет, Vol 0, Iss 19, Pp 116-121 (2018)

Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic. Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::668306d53332e104494b7765d6341fdc
https://doi.org/10.21518/2079-701x-2018-19-116-121

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání